BioMarin Pharmaceutical (BMRN) Stock

NASDAQ / Healthcare / Biotechnology

$56.01

−0.20% Close Nov 6

BMRN stock daily candlestick chart with 50, 150 and 200-day moving averagesOpen interactive chart
One year of daily prices through the Nov 6, 2026 close. This page updates by about 4 AM ET after each trading day. The interactive chart has the full history.

BMRN stock price and performance

BMRN stock closed at $56.01 on Nov 6, 2026. The tables below use that final daily session.

Last close
$56.01
Day range
$55.00 to $56.08
52-week range
$49.26 to $70.98
From 52-week high
−21.1%
Average volume (50 days)
2.3M
1 week
−4.3%
1 month
+2.0%
3 months
−18.7%
Year to date
−5.8%
1 year
+6.1%
3 years
−33.3%
5 years
−29.3%

Is BMRN stock in an uptrend?

No, BMRN stock is in a downtrend: it does not meet the Minervini Trend Template criteria and neither Daily Pivot Breakout momentum filter is active. Price is below its 200-day moving average.

Daily Pivot momentum filters
0 of 2 active
100-day ROC
+1.6% filter at 40%: off
100-day EMA slope
+6.6% filter at 25%: off
Trend state
Downtrend
Minervini Trend Template
Not met on the latest scan
50-day average
Below
150-day average
Below
200-day average
Below
200-day slope (1 month)
−0.44%
ATR (14) % of price
3.50%

Momentum filters from the Daily Pivot Breakout indicator: 100-day rate of change and 100-day EMA slope, each against its minimum.

Is BMRN stock in a Stage 2 uptrend?

No. BMRN stock is in Stage 3 (topping) by our Weinstein stage analysis: its 30-week moving average has flattened after an advance.

Weinstein stage
Stage 3 (topping)
30-week SMA
$58.62
30-week slope (4 weeks)
+0.39%
Mansfield RS vs SPY
-5.75

Weinstein stage analysis uses weekly closes against the 30-week moving average and Mansfield relative strength versus SPY. See the free Stage 2 stocks screener.

BMRN support and resistance levels

LevelPriceFrom close
50-day SMA$59.69+6.6%
30-week SMA$58.62+4.7%
150-day SMA$58.48+4.4%
200-day SMA$58.45+4.4%
Daily Pivot resistance (pivot high)$57.59+2.8%
21-day EMA$56.78+1.4%
9-day EMA$56.45+0.8%
Latest Daily Pivot low$53.90−3.8%

Levels above the close act as resistance, levels below as support. Last close $56.01.

BMRN breakout and scanner signals

ScannerLast signal (free view, 5 sessions late)Past year
VCPNone in the last year0
RSI DivergenceNov 5, 20250
Weinstein Stage AnalysisSep 18, 202629
Daily Pivot BreakoutNone in the last year0
Minervini Trend TemplateSep 16, 20261
Episodic PivotNone in the last year0
Ichimoku TK crossSep 14, 2026 (bearish)10
9/21 EMA crossSep 17, 2026 (bearish)10
Golden / Death CrossJul 22, 20263
RS RatingNone in the last year0

BMRN seasonality by month

  1. Jan+3.9%62% up
  2. Feb+1.6%48% up
  3. Mar+0.2%44% up
  4. Apr−2.1%48% up
  5. May+0.8%52% up
  6. Jun+1.7%59% up
  7. Jul+4.0%67% up
  8. Aug−0.6%56% up
  9. Sep−2.0%41% up
  10. Oct−2.3%41% up
  11. Nov+6.8%85% up
  12. Dec+4.1%65% up

Average monthly return over 26+ years of stored daily closes, and the share of years each month closed higher.

BMRN earnings history

ReportedEPS estimateEPS actualSurprise
Nov 2, 2026$-0.11$0.23+309.1%
Oct 13, 2026$13.09$17.01+30.0%
Aug 6, 2026$0.95$1.20+26.3%
Jul 23, 2026$3.32$3.52+6.0%
Jul 9, 2026$0.04$-0.02−150.0%

BMRN bull and bear case

What looks strong

  • The 50, 150 and 200-day averages are stacked in uptrend order.

What looks weak

  • Neither Daily Pivot momentum filter is active (100-day ROC 1.6%, 100-day EMA slope 6.6%; the filters need 40% and 25%).
  • Does not meet the Minervini Trend Template on the latest scan.
  • Price is below the 200-day moving average, which is falling.
  • Net income over the last 12 months is negative.

Drawn only from the data on this page. Not a recommendation.

BMRN news and SEC filings, last 30 days

Source: SEC EDGAR.

BMRN insider trading and risks

Buys, last 90 days
0 ($0)
Sales, last 90 days
0 ($0)
Buys, last 12 months
0 ($0)
Sales, last 12 months
0 ($0)

Risk flags from the data

  • Net income over the last 12 months is negative.

Insider trades: SEC Form 4 open-market purchases and sales.

BMRN valuation and fundamentals

Market cap
$10.85B
Enterprise value
$14.31B
P/E (trailing)
151.6
P/E (forward)
8.8
PEG
-1.86
Price to sales
2.97
Price to book
1.73
EV to EBITDA
16.7
Gross margin
+79.5%
Operating margin
+26.6%
Profit margin
−0.5%
Return on equity
−0.3%
Revenue (TTM)
$3.66B
Revenue growth (quarter, y/y)
+32.0%
Cash
$736.0M
Debt
$4.19B
Beta
0.23
Fiscal yearRevenueNet incomeFree cash flow
2025$3.22B$348.9M$828.0M
2024$2.85B$426.9M$502.6M
2023$2.42B$167.6M$4.7M
2022$2.10B$141.6M$174.2M

BMRN dividends and splits

Dividend yield
0.00%
Payout ratio
0.0%

Who owns BMRN?

Shares outstanding
193.5M
Float
192.8M
Held by insiders
+0.3%
Held by institutions
+103.1%
Short interest (% of shares)
+6.2%
Days to cover
5.3

What does BioMarin Pharmaceutical Inc. do?

CEO
Mr. Alexander Hardy
Employees
3,221
Headquarters
San Rafael, CA, United States

Updated Nov 6, 2026. Prices and fundamentals: Source: Twelve Data. Filings and insider trades: SEC EDGAR. Charts: TradingView Lightweight Charts. Educational information, not investment advice.